Tim Watkins, CMO & Head of Development at Contineum Therapeutics, Inc. (CTNM), sold 3,611 shares at $12.06 ($44K) on 2025-12-29, disclosed to the SEC on 2025-12-30.
Scheduled sale ($44k) by CMO & Head of Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| CTNM | SELL | 2026-01-30 | $102K | — | Filing → |